Clinical Trials Browser

N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide × Clear all

NCT06235801 2026-06-02

A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia

Phase 1/2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid

NCT06150157 2026-05-12

A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

Phase 1 Recruiting

Neoplasms

NCT03441113 2026-04-20

Extended Access of Momelotinib in Adults With Myelofibrosis

Phase 2 Active not recruiting

Neoplasms, Primary Myelofibrosis

NCT07071155 2026-03-27

M-HArbOr

Phase EARLY_PHASE1 Recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Neutrophilic, Chronic, Leukemia, Myelomonocytic, Chronic

NCT02124746 2023-06-18

Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia

Phase 2 Completed

87 enrolled 17 charts

Hematologic Diseases, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT01998828 2020-04-20

Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia

Phase 2 Terminated

Blood Coagulation Disorders, Blood Platelet Disorders, Bone Marrow Diseases, Hematologic Diseases, Hemorrhagic Disorders, Myeloproliferative Disorders, Polycythemia, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis

NCT02206763 2019-02-01

Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase 1 Terminated

EGFR Mutated EGFR TKI Naive Metastatic NSCLC

NCT02258607 2019-02-01

Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase

Phase 1 Terminated

Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer